Lecigon development statusEvaRis182022-10-25T11:45:40+02:00
Sweden and EU
Lecigon was granted marketing authorization by the Swedish Medical Products Agency (MPA) on Oct 5th 2018, followed by a Swedish pricing and reimbursement approval in March 2019.
In September 2019, the Swedish MPA confirmed End of Procedure according to the European Mutual Recognition Procedure (MRP) including Denmark, Finland and Norway. National market authorizations in these countries are expected to be finalized end of October, when the commercialization can be initiated.
In October 2020 Lobsor Pharmacetucials was acquired by STADA Arzneimittel AG. Further development and commercialization of Lecigon is managed by yet another STADA affiliate, Britannia Pharmaceuticals.